A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)

L Gargiulo; L Ibba; P Malagoli; F Amoruso; G Argenziano; A Balato; F Bardazzi; M Burlando; C G Carrera; G Damiani; P Dapavo; V Dini; G Fabbrocini; C Franchi; F M Gaiani; G Girolomoni; C Guarneri; C Lasagni; F Loconsole; A V Marzano; M Maurelli; M Megna; D Orsini; F Sampogna; M Travaglini; M Valenti; A Costanzo; A Narcisi

doi:10.1111/jdv.19464

A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e113-e116. doi: 10.1111/jdv.19464. Epub 2023 Aug 29.

Authors

L Gargiulo^{1

2}, L Ibba^{1

2}, P Malagoli³, F Amoruso⁴, G Argenziano⁵, A Balato⁵, F Bardazzi⁶, M Burlando⁷, C G Carrera⁸, G Damiani^{9

10}, P Dapavo¹¹, V Dini¹², G Fabbrocini¹³, C Franchi¹⁰, F M Gaiani³, G Girolomoni¹⁴, C Guarneri¹⁵, C Lasagni¹⁶, F Loconsole¹⁷, A V Marzano^{8

18}, M Maurelli¹⁴, M Megna¹³, D Orsini¹⁹, F Sampogna²⁰, M Travaglini²¹, M Valenti^{1

2}, A Costanzo^{1

2}, A Narcisi¹

Affiliations

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Milan, Italy.
³ Department of Dermatology, Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.
⁴ Dermatology Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
⁵ Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
⁶ Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy.
⁷ Department of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁸ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁹ Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy.
¹⁰ Clinical Dermatology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy.
¹¹ Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
¹² Dermatology Unit, Department of Clinical and Experimental Medicine Ospedale Santa Chiara, Pisa, Italy.
¹³ Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
¹⁴ Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
¹⁵ Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Unit of Dermatology, University of Messina, AOU Policlinico G. Martino, Messina, Italy.
¹⁶ Dermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, Italy.
¹⁷ Department of Dermatology, University of Bari, Bari, Italy.
¹⁸ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
¹⁹ UOC Clinical Dermatology - Dermatological Institute S. Gallicano, IRCCS, Rome, Italy.
²⁰ Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata (IDI) IRCCS, Rome, Italy.
²¹ U.O.S.D. Dermatologica - Centro per la Cura Della Psoriasi, Brindisi, Italy.

PMID: 37611277
DOI: 10.1111/jdv.19464

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal*
Humans
Italy
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

risankizumab
Antibodies, Monoclonal